{"ticker": {"uuid": "1eb952e9-ecd1-492c-83b1-06dec662e405", "symbol": "HLUN-A", "name": "H. Lundbeck A/S", "exchange": "CPH", "country": "DK", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T14:09:58+00:00", "published_display": "18 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nordea raises target price for Lundbeck to DKK60 (57), reiterates buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX1FUYzRpMGhZX2RLV084NXlCZV96VVd1VkViQjBVVmFaSnNJcTFYUjRZWHNjLWx1VFVJbm9QTGhCZDRmdjNCVEdHZG9BVlZfUjNmYnpoMmI5RlVoQTJEUE9FbVZsTlA2THlFWWRTZlRKTjROampwY2dBeldScmNZMS1zQ0FTWjV3WDh1ZnAxdE83dUlwdlM2aTNJVENVNEZnQy1tdVN4Wnh6QzRTODVRT1d6bVhKSkZXSUZBUnM2TUdBSjI0?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-18T05:41:23+00:00", "published_display": "18 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck reports early success for experimental Cushing's disease treatment (HLBBF:OTCMKTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNekQ5VWdFaVZ6aHpWUWJ4S2hsWFBINHpLNVFkVVpDblNQR2lCMTZUeFBkU3lGQ3hYeF9WWmxiZ3ZXTmFRVkJtellWTFVfVUJuWGI4ZVJOVEduUDZKTXcwb19SaHVBRkJ1UnpJaEpTclVXN1EzQXNUWTV4RDVIZFdvMnBFQnRYSmVvRkJuTmR6ejk5aEc4LWFucWJwek42QkZlSjJrMWdhTnRLd2dJd0FBQ1pn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-14T20:24:33+00:00", "published_display": "14 Jun 2026 20:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment - Slideshow (OTCMKTS:HLBBF) 2026-06-06", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNMU84Umx2bXV2QjBjM2RfX0FEMmc1a1JqSzFNMkk3Ql9tNl9ReVBocm5ZNHVPR1haYVNkWkE2SG5ySkRXX2R1Rmh3ZzRySDcwMXN3T3pKcl9NS3VtOFJoMy1IMUt5a19LZGVGdVM4OE43VGI5RlV6SUFNX3ZSdkNDdG1ZVERwaGZ6SkxyNWtRUEEzTWY3NFEyVTZyV3hZdmxMY3JvMi1talZkZ1RyaHRqUHFoN0RUWGxQRjlnUUt2UHk4azlRQmQ0OTRJMWZCdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQeVNfMDRXdzhmTXR3RDFjaXhGZkVjbnV4NkNZbmVIb1hLOUJTOGo2Y3dDOU5vczQ4TWFWR05SZENUX0FZVmVjM1R4cnRjZUlKMEFqTDNRNkpJc2VTMlM1Si05bGxTVHhBWGVDSE5UZEw5ZFVqUExPODJ0ZEVTRS1DdG9uMW9HQzl0N2xKM0o4RlRCbC1mWGh5MTIySFI5R1oxTnRxNUNka3ctRUptTV9saDB2ZUxra2ZmOXlneGZFS29pdmR1dlpr?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck shares slip on pessimistic earnings outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQNExTbjYxVnJ3aWNNdXdCMHV6blAtZnV6dGR1d0FMNDVKV2UtZUZYY0lUUTkzS2ZLdVhYSVVNYnJrT19CcW9lY2RHLWJmN0ZRRjQ3OHhjRHJYSURlWlNmVEtTbFJ4X1V5aHJHOHRqSzJlMzY4TGpzTVI0c3Zldk5VMngtbmdmVXRJOGlLNmN2Y3VPS2NQUGR2elZrVXM?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lundbeck Still Attractive After 12.6% Monthly Surge and Positive Neurology Pipeline Updates?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H. Lundbeck A/S : Lundbeck", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNbDVpRmJxcW90allLVTN1YUM0RF94MEN5LVpRd3RXeTZhcmFpa3MtaWU5WnJJbUY3SEcyVFZlZXl5VWp4XzRuQlZrREp4dGxKbXZVMHJXb1dUdFp4T04yTU0zWnBGR1FGRS1HMzU4UmVsTUUzcnV5VFFFeUl6b2RYZkl1NE1uaEhkUm1LRDhsYlFmcUVPRlZDRTlua3VQeHhkVzlhNFFGTTA2RDRubktjU3B6MlVlU3UtOFdwNS04WnBuaTB4V3d1VHhDSmtSZ3EyWGxV?oc=5", "source_name": "marketscreener.com", "published_at": "2024-11-20T08:00:00+00:00", "published_display": "20 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck to take over Longboard Pharma in US$2.6bn transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOekNUcnQxMHhpZDZLbzNQcjZ6U2lidGhORk03NW0yQ24wamZ6WThCWlNCX0tULVBVMUJKcFhRblVMY1B5b0JVaF8wdzBCb3A0OVZFQ18wQ0RwcjI4dnNTdFZXcGlTVmtmTW5ZOFhSQzRuVmNULUswRnQ2VmdXS2YzanNKaFFEVmJFVDN5bzF4Ujk1TFdGY3VzOHU3ZEpJVW5SS1ZLNW1FV3djZDA2Rmc?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2024-10-15T07:00:00+00:00", "published_display": "15 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNRGtkcW9paWpfTEdCLUstdS1HUXFOdEhNREx1RzRkb011bkpWa1pVbmR5c3JhZXdWbUJaX29rblI3ZncxWXhQaWZNMmFlSDlfWjRSZjFyZy1EV1dCb20zcG1sbEdpdWpmb1hQbmZHNUdCbkN5VHVONFBKbVE3R0IwY0FnSVVOdzZQVXI5cF9OWlJWMS1XOWR3aWl3Yw?oc=5", "source_name": "Reuters", "published_at": "2024-10-14T07:00:00+00:00", "published_display": "14 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxObDFlSzRzRVNielp3ZW5uVHdLNkE1dWlIejZUdF9CaGZxdExkWXpnaGMwcFBMMkVkLUhmbDhJX3VCdVVhdDZNZk9pWFo4Zkk1cG5qTG5nM3g3S2QzLXRWSXhFVzhTUUdwclBvRktPVXpDTkxOR1hBOHphemtIZEhTSVZXWU9FMklfOUxhTDEyM3FrVXh0Q1FiUnlQSllJc1AySFB6QjU3VGxPbFgtYVA0VnVXWm5DRlhmN2lsVnNDY2h0QVJTdDZfVE01OG5ZUFFOUEU4RVdsTnl4cHl4YXg3X2NYaTNXbEV6dHp3Zk4yWmFmVFBJVDNMRlY1dkVmSFBpdkE?oc=5", "source_name": "Business Wire", "published_at": "2024-10-14T07:00:00+00:00", "published_display": "14 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOZ0VsUUZWWEQwdFNpNUZvd3NBWm1kZGNPaV9uX09aVnhMMTg1b2tVSnczMHc0N2ZOOHJ4alNib2s2SnYtb3l4MFVZeVpkQ25qUnVRTEstQWF3RlRTTFZaOXBKMWpubnRpME10WUZrUXJTZUc3VGpnRGthOXVZa1FPcjVBaFppcV9kOGZ0d0JPSk5CbVNOWGc?oc=5", "source_name": "MedCity News", "published_at": "2019-09-16T07:00:00+00:00", "published_display": "16 Sep 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck to acquire Alder BioPharmaceuticals \u2013 a company", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2019-09-16T07:00:00+00:00", "published_display": "16 Sep 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck Schizophrenia Drug Fails to Differentiate Itself from Conventional Therapies, Stocks Plunge", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZ1V5d18zbUFfaTFUMXdBZmItckdJS2NGclp6VlpVWXRTd1V2eEEtWUtnbVBxYkdUZzVKOXYxYnJCNEtTQkNuSjV3a3k2NHJxYzg2YnllZFh4UC1zMFRJajg4dGZlV1pCZVRaNUx2X3NpbUFVbmhUaGVvUWFvOUxvYlhTOUUxbnk5eXRzVzhYN2U1d2Z5S3NJWTNnSHdKVnhwVGx0VjZUTWc2Y1ZTNGxYcHJ4NnR0aUtBZEx4NmNCWmtjUQ?oc=5", "source_name": "BioSpace", "published_at": "2018-10-26T07:00:00+00:00", "published_display": "26 Oct 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T14:09:58+00:00", "published_display": "18 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nordea raises target price for Lundbeck to DKK60 (57), reiterates buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX1FUYzRpMGhZX2RLV084NXlCZV96VVd1VkViQjBVVmFaSnNJcTFYUjRZWHNjLWx1VFVJbm9QTGhCZDRmdjNCVEdHZG9BVlZfUjNmYnpoMmI5RlVoQTJEUE9FbVZsTlA2THlFWWRTZlRKTjROampwY2dBeldScmNZMS1zQ0FTWjV3WDh1ZnAxdE83dUlwdlM2aTNJVENVNEZnQy1tdVN4Wnh6QzRTODVRT1d6bVhKSkZXSUZBUnM2TUdBSjI0?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-18T05:41:23+00:00", "published_display": "18 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck reports early success for experimental Cushing's disease treatment (HLBBF:OTCMKTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNekQ5VWdFaVZ6aHpWUWJ4S2hsWFBINHpLNVFkVVpDblNQR2lCMTZUeFBkU3lGQ3hYeF9WWmxiZ3ZXTmFRVkJtellWTFVfVUJuWGI4ZVJOVEduUDZKTXcwb19SaHVBRkJ1UnpJaEpTclVXN1EzQXNUWTV4RDVIZFdvMnBFQnRYSmVvRkJuTmR6ejk5aEc4LWFucWJwek42QkZlSjJrMWdhTnRLd2dJd0FBQ1pn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-14T20:24:33+00:00", "published_display": "14 Jun 2026 20:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment - Slideshow (OTCMKTS:HLBBF) 2026-06-06", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNMU84Umx2bXV2QjBjM2RfX0FEMmc1a1JqSzFNMkk3Ql9tNl9ReVBocm5ZNHVPR1haYVNkWkE2SG5ySkRXX2R1Rmh3ZzRySDcwMXN3T3pKcl9NS3VtOFJoMy1IMUt5a19LZGVGdVM4OE43VGI5RlV6SUFNX3ZSdkNDdG1ZVERwaGZ6SkxyNWtRUEEzTWY3NFEyVTZyV3hZdmxMY3JvMi1talZkZ1RyaHRqUHFoN0RUWGxQRjlnUUt2UHk4azlRQmQ0OTRJMWZCdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQeVNfMDRXdzhmTXR3RDFjaXhGZkVjbnV4NkNZbmVIb1hLOUJTOGo2Y3dDOU5vczQ4TWFWR05SZENUX0FZVmVjM1R4cnRjZUlKMEFqTDNRNkpJc2VTMlM1Si05bGxTVHhBWGVDSE5UZEw5ZFVqUExPODJ0ZEVTRS1DdG9uMW9HQzl0N2xKM0o4RlRCbC1mWGh5MTIySFI5R1oxTnRxNUNka3ctRUptTV9saDB2ZUxra2ZmOXlneGZFS29pdmR1dlpr?oc=5", "source_name": "marketscreener.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck shares slip on pessimistic earnings outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQNExTbjYxVnJ3aWNNdXdCMHV6blAtZnV6dGR1d0FMNDVKV2UtZUZYY0lUUTkzS2ZLdVhYSVVNYnJrT19CcW9lY2RHLWJmN0ZRRjQ3OHhjRHJYSURlWlNmVEtTbFJ4X1V5aHJHOHRqSzJlMzY4TGpzTVI0c3Zldk5VMngtbmdmVXRJOGlLNmN2Y3VPS2NQUGR2elZrVXM?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lundbeck Still Attractive After 12.6% Monthly Surge and Positive Neurology Pipeline Updates?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H. Lundbeck A/S : Lundbeck", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNbDVpRmJxcW90allLVTN1YUM0RF94MEN5LVpRd3RXeTZhcmFpa3MtaWU5WnJJbUY3SEcyVFZlZXl5VWp4XzRuQlZrREp4dGxKbXZVMHJXb1dUdFp4T04yTU0zWnBGR1FGRS1HMzU4UmVsTUUzcnV5VFFFeUl6b2RYZkl1NE1uaEhkUm1LRDhsYlFmcUVPRlZDRTlua3VQeHhkVzlhNFFGTTA2RDRubktjU3B6MlVlU3UtOFdwNS04WnBuaTB4V3d1VHhDSmtSZ3EyWGxV?oc=5", "source_name": "marketscreener.com", "published_at": "2024-11-20T08:00:00+00:00", "published_display": "20 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck to take over Longboard Pharma in US$2.6bn transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOekNUcnQxMHhpZDZLbzNQcjZ6U2lidGhORk03NW0yQ24wamZ6WThCWlNCX0tULVBVMUJKcFhRblVMY1B5b0JVaF8wdzBCb3A0OVZFQ18wQ0RwcjI4dnNTdFZXcGlTVmtmTW5ZOFhSQzRuVmNULUswRnQ2VmdXS2YzanNKaFFEVmJFVDN5bzF4Ujk1TFdGY3VzOHU3ZEpJVW5SS1ZLNW1FV3djZDA2Rmc?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2024-10-15T07:00:00+00:00", "published_display": "15 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNRGtkcW9paWpfTEdCLUstdS1HUXFOdEhNREx1RzRkb011bkpWa1pVbmR5c3JhZXdWbUJaX29rblI3ZncxWXhQaWZNMmFlSDlfWjRSZjFyZy1EV1dCb20zcG1sbEdpdWpmb1hQbmZHNUdCbkN5VHVONFBKbVE3R0IwY0FnSVVOdzZQVXI5cF9OWlJWMS1XOWR3aWl3Yw?oc=5", "source_name": "Reuters", "published_at": "2024-10-14T07:00:00+00:00", "published_display": "14 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxObDFlSzRzRVNielp3ZW5uVHdLNkE1dWlIejZUdF9CaGZxdExkWXpnaGMwcFBMMkVkLUhmbDhJX3VCdVVhdDZNZk9pWFo4Zkk1cG5qTG5nM3g3S2QzLXRWSXhFVzhTUUdwclBvRktPVXpDTkxOR1hBOHphemtIZEhTSVZXWU9FMklfOUxhTDEyM3FrVXh0Q1FiUnlQSllJc1AySFB6QjU3VGxPbFgtYVA0VnVXWm5DRlhmN2lsVnNDY2h0QVJTdDZfVE01OG5ZUFFOUEU4RVdsTnl4cHl4YXg3X2NYaTNXbEV6dHp3Zk4yWmFmVFBJVDNMRlY1dkVmSFBpdkE?oc=5", "source_name": "Business Wire", "published_at": "2024-10-14T07:00:00+00:00", "published_display": "14 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOZ0VsUUZWWEQwdFNpNUZvd3NBWm1kZGNPaV9uX09aVnhMMTg1b2tVSnczMHc0N2ZOOHJ4alNib2s2SnYtb3l4MFVZeVpkQ25qUnVRTEstQWF3RlRTTFZaOXBKMWpubnRpME10WUZrUXJTZUc3VGpnRGthOXVZa1FPcjVBaFppcV9kOGZ0d0JPSk5CbVNOWGc?oc=5", "source_name": "MedCity News", "published_at": "2019-09-16T07:00:00+00:00", "published_display": "16 Sep 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck to acquire Alder BioPharmaceuticals \u2013 a company", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2019-09-16T07:00:00+00:00", "published_display": "16 Sep 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lundbeck Schizophrenia Drug Fails to Differentiate Itself from Conventional Therapies, Stocks Plunge", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZ1V5d18zbUFfaTFUMXdBZmItckdJS2NGclp6VlpVWXRTd1V2eEEtWUtnbVBxYkdUZzVKOXYxYnJCNEtTQkNuSjV3a3k2NHJxYzg2YnllZFh4UC1zMFRJajg4dGZlV1pCZVRaNUx2X3NpbUFVbmhUaGVvUWFvOUxvYlhTOUUxbnk5eXRzVzhYN2U1d2Z5S3NJWTNnSHdKVnhwVGx0VjZUTWc2Y1ZTNGxYcHJ4NnR0aUtBZEx4NmNCWmtjUQ?oc=5", "source_name": "BioSpace", "published_at": "2018-10-26T07:00:00+00:00", "published_display": "26 Oct 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 42, "total_relevant": 15, "sentiment_summary": {"positive": 3, "negative": 0, "neutral": 12, "score": 56, "total": 15, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 5.3, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 1.45, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.45, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 3, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 36.6, "latest_week": "2026-06-19", "one_week_move": 0.1, "four_week_move": 2.5, "twelve_week_move": 14.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.904209, "market_dynamics_buy_signal": false, "relative_strength": 6.398398, "fair_value_gap": 17.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 51.601, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +2.5% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 3}, {"label": "marketscreener.com", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "The Pharma Letter", "count": 1}, {"label": "European Biotechnology Magazine", "count": 1}, {"label": "Reuters", "count": 1}, {"label": "Business Wire", "count": 1}, {"label": "MedCity News", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 15}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 9}, {"label": "Earnings", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "15", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +2.5% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data"}], "updated_at": "2026-06-22T15:07:31.744695+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}